Work

Supplemental Tables from Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy

Year: 2023

Type: supplementary-materials

Abstract: Table S1. Subject demographics and baseline characteristics Table S2. Tumor response as assessed by RECIST 1.1 and biochemical response

DOI: 10.1158/1078-0432.22465800.v1

Authors: Bradley J. Monk, Andrea Facciabene, William E. Brady, Carol A. Aghajanian, Paula M. Fracasso, Joan L. Walker, Heather A. Lankes, Kristi L. Manjarrez, Gwenn-äel H. Danet-Desnoyers, Katherine M. Bell-McGuinn, Carolyn K. McCourt, Alexander Malykhin, Robert M. Hershberg, George Coukos

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361818366

Cites:

Cited by:

Related to: 10